Literature DB >> 3973964

Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

J S Wolinsky, M N Waxham, A C Server.   

Abstract

Newborn Syrian hamsters were challanged with an intracerebral inoculum containing 128 50% lethal doses of the Kilham strain of mumps virus and treated 24 h later with a single intraperitoneal injection of mouse monoclonal antibody. Monoclonal antibodies reactive with epitopes on the fusion glycoprotein of mumps virus could not inhibit hemagglutination or neutralize infectivity in vitro and failed to provide biologically important protection against the in vivo infection. In contrast, monoclonal antibodies reactive with epitopes on the hemagglutinin-neuraminidase glycoprotein of mumps virus inhibited hemagglutination and neutralized infectivity in vitro and protected infected animals from the otherwise lethal central nervous system virus infection. Similar protection was provided by both purified immunoglobulin and F(ab')2 fragments. Immuno-cytochemical and virological studies showed diminished virus antigen and virus titers in the brains of successfully treated animals. It appears that a topographically restricted region of the hemagglutinin-neuraminidase molecule of the Kilham strain of mumps virus is of critical importance for immune recognition by the infected host.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3973964      PMCID: PMC254700     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Polypeptides of mumps virus.

Authors:  S C Jensik; S Silver
Journal:  J Virol       Date:  1976-02       Impact factor: 5.103

2.  Immunological properties of purified mumps virus glycoproteins.

Authors:  C Orvell
Journal:  J Gen Virol       Date:  1978-12       Impact factor: 3.891

3.  A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.

Authors:  F X Heinz; R Berger; W Tuma; C Kunz
Journal:  Virology       Date:  1983-04-30       Impact factor: 3.616

4.  The effects of monoclonal antibodies on biologic activities of structural proteins of Sendai virus.

Authors:  C Orvell; M Grandien
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Immunochemical identification of rubella virus hemagglutinin.

Authors:  M N Waxham; J S Wolinsky
Journal:  Virology       Date:  1983-04-15       Impact factor: 3.616

6.  A comparison of the structural polypeptides of five strains of mumps virus.

Authors:  M McCarthy; R T Johnson
Journal:  J Gen Virol       Date:  1980-01       Impact factor: 3.891

7.  Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody.

Authors:  G J Letchworth; J A Appleton
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

8.  Breakdown of the blood--cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus. Post-exposure treatment with monoclonal antibody promotes recovery.

Authors:  P C Doherty; W Gerhard
Journal:  J Neuroimmunol       Date:  1981-09       Impact factor: 3.478

9.  Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody.

Authors:  M J Buchmeier; H A Lewicki; P J Talbot; R L Knobler
Journal:  Virology       Date:  1984-01-30       Impact factor: 3.616

10.  Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin.

Authors:  K W Rammohan; H F McFarland; D E McFarlin
Journal:  Nature       Date:  1981-04-16       Impact factor: 49.962

View more
  23 in total

1.  Complete nucleotide sequence of a mumps virus genotype I strain isolated in Korea.

Authors:  Joo-Yeon Lee; Byoung-Kuk Na; Ho-Dong Lee; Sung-Wook Chang; Kyung-Ae Kim; Jee-Hee Kim; Hae-Wol Cho; Joon Kim; Chun Kang
Journal:  Virus Genes       Date:  2004-03       Impact factor: 2.332

2.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

4.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis.

Authors:  A Löve; R Rydbeck; G Utter; C Orvell; K Kristensson; E Norrby
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

Review 6.  [Mumps vaccines: virological basis].

Authors:  A Ströhle; D Germann
Journal:  Soz Praventivmed       Date:  1995

7.  Antibody-induced restriction of viral gene expression in measles encephalitis in rats.

Authors:  U G Liebert; S Schneider-Schaulies; K Baczko; V ter Meulen
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity.

Authors:  G A Linde; M Granström; C Orvell
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

9.  Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies.

Authors:  M N Waxham; D C Merz; J S Wolinsky
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

10.  Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice.

Authors:  J Stanley; S J Cooper; D E Griffin
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.